US OptionsDetailed Quotes
ACHV241220C5000
- 0.10
- 0.000.00%
15min DelayClose Nov 22 16:00 ET
0.00High0.00Low
0.10Open0.10Pre Close0 Volume5.15K Open Interest5.00Strike Price0.00Turnover110.43%IV18.88%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier27DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.3643Delta0.2906Gamma15.60Leverage Ratio-0.0092Theta0.0010Rho5.68Eff Leverage0.0044Vega
Achieve Life Stock Discussion
Sign in to post a comment
$Achieve Life (ACHV.US)$
Achieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes
Achieve Life Sciences has initiated the ORCA-OL clinical trial to evaluate the long-term safety of cytisinicline, a treatment for smoking and nicotine dependence. The open-label trial involves 29 U.S. sites and aims to collect data required for a New Drug Application (NDA) submission expected in the first ...
Achieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes
Achieve Life Sciences has initiated the ORCA-OL clinical trial to evaluate the long-term safety of cytisinicline, a treatment for smoking and nicotine dependence. The open-label trial involves 29 U.S. sites and aims to collect data required for a New Drug Application (NDA) submission expected in the first ...
$Achieve Life (ACHV.US)$
NEWS
Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine
NEWS
Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine
1
$Annovis Bio (ANVS.US)$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies (TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals (TFFP.US)$ 14% Clinical programs update
$Jaguar Health (JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin (SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems (DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences (SLS.US)$ 0% Closes $20M offering & private placement
$Immunic (IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics (NRIX.US)$ 0...
$Taysha Gene Therapies (TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals (TFFP.US)$ 14% Clinical programs update
$Jaguar Health (JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin (SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems (DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences (SLS.US)$ 0% Closes $20M offering & private placement
$Immunic (IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics (NRIX.US)$ 0...
11
1
$Achieve Life Sciences Inc(ACHV.US)$ The fortunes of the company rely entirely on a drug that is thinly patented and available for any company to use outside of the United States, making it the sole market upon which the ACHV valuation is based. This week the Biden administration signaled an incoming ban of addictive nicotine cigarettes in the United States, creating the possibility for short term lift, however analysts are likely to conclude the new laws badly undermine future revenue potential for ACHV. ...
1
1
$Achieve Life (ACHV.US)$ if you're selling this you're stupid. Good luck. You'll need it
No comment yet
Stock_Drift : Mmmmm, nice.
Bigmoney Dreamer : Bidders overtaking askers need to break 6.00$ otherwise very very long hold ..anyway buy signal in quarterly may can break over within next 3-6 months